{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:16:40Z","timestamp":1787239000925,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent studies show that sodium-glucose linked transporter 2 inhibitors (SGLT2is) reduce blood glucose and provide cardiovascular benefits, decreasing acute myocardial ischemia\/reperfusion injury in patients with acute myocardial infarction (AMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This meta-analysis aims to thoroughly assess the clinical effectiveness of SGLT2is in the treatment of AMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Randomized controlled trials (RCTs) evaluating the efficacy of SGLT2is in combination with guideline-directed medical therapy (GDMT) for AMI were retrieved from major databases: PubMed, Cochrane Library, Embase, Medline, and Web of Science. At the same time, clinical trial registries (\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      and the WHO International Clinical Trials Registry Platform) were searched, covering all published literature up to May 2025. Using the Cochrane Collaboration for assessing the risk of bias, two independent reviewers preliminarily screened and assessed the studies according to the preset inclusion criteria. Meta-analysis was conducted using RevMan 5.4 software, and StataMP 16.0 was used to evaluate publication bias. The quality of evidence was graded according to recommended procedures for assessing and evaluating the evidence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five RCTs with a total of 881 patients were included in this analysis. According to a meta-analysis, SGLT2is and GDMT significantly reduced NT-proBNP (RR = \u221289.82, 95% CI -96.28 to \u221283.35; p &amp;lt; 0.00001) and enhanced the 12-week left ventricular ejection fraction (LVEF) (RR = 6.32, 95% CI -4.95 to 17.60; p &amp;lt; 0.00001). Evaluation of additional cardiac structural and functional characteristics showed that the SGLT2i + GDMT group showed significantly reduced left atrial volume (LAV) (RR = \u22123.86, 95% CI -6.33 to \u22121.38; p = 0.002) and left atrial volume index (LAVI) (RR = \u22121.67, 95% CI -3.13 to \u22120.20; p = 0.03) when compared to the control group. There were decreases in LVESVI, LVEDVI, LVEDD, LVESD, LVESV, and LVEDV. Furthermore, subgroup analyses based on the LVEF at admission and the site of the infarct in AMI patients were carried out. Treatment with SGLT2i + GDMT led to a significantly higher improvement in the LVEF \u226440% group than in the LVEF &amp;gt;40% group (MD = 5.20, 95% CI 2.74 to 7.66; p &amp;lt; 0.0001). The cardiotonic troponin I (cTnI) levels in the LVEF &amp;gt;40% group showed a declining trend starting at 8\u00a0h post-onset and a notable improvement at 40\u00a0h post-onset. Significant improvement in cTnI levels was observed in the LVEF \u226440% group after 56\u00a0h post-onset (MD = \u22128.40, 95% CI \u221213.74 to \u22123.06; p = 0.002). Regarding the effect of the infarct location on LVEF recovery, patients with AMI treated with SGLT2i + GDMT demonstrated a significant improvement in LVEF, regardless of whether the myocardial infarction was in the anterior wall (MD = 4.20, 95% CI 0.88 to 7.52; p = 0.01) or the non-anterior wall (MD = 3.90, 95% CI 0.63 to 7.17; p = 0.02). As early as 16\u00a0h after commencement, both groups\u2019 cTnI levels showed a declining trend. By 24\u00a0h after the onset, non-anterior myocardial infarction patients showed a substantial improvement in cTnI levels (MD = \u22121.70, 95% CI \u221211.92 to \u22122.28; p = 0.004). However, ST-segment resolution showed no significant differences between the two groups. The SGLT2i + GDMT group\u2019s incidence rate for the primary endpoint major adverse cardiovascular events (MACEs) was nearly identical to that of the control group. Recurrent myocardial infarction (RR = 0.64, 95% CI 0.16\u20132.55; p = 0.53), stroke (RR = 2.71, 95% CI 0.11\u201368.25; p = 0.54), and cardiovascular disease-related death (RR = 1.47, 95% CI 0.29\u20137.56; p = 0.64) did not differ significantly from one another. The incidence of MACEs in the experimental group was essentially comparable to that in the control group. For other primary endpoints, the incidence of re-admission for heart failure showed a downward trend in the experimental group compared with the control group. Furthermore, although no significant hepatic or renal dysfunction was reported in the studies, meta-analysis indicated that SGLT2i combined with GDMT increased the incidence of drug-related adverse events, which primarily manifested as higher rates of genitourinary infections and acute kidney injury (RR = 1.88, 95% CI 1.03\u20133.42; p = 0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Available data suggest that SGLT2i intervention may ameliorate detrimental early ventricular remodeling in individuals who have had an AMI, improve cardiac function, and aid in the recovery of cardiac function and structure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1699066","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:33:04Z","timestamp":1764253984000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of SGLT2 inhibitors on cardiac remodeling after myocardial infarction: an updated meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Ma Li","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1007\/s00210-024-03739-8","article-title":"The efficacy and safety of empagliflozin on outcomes of patients with myocardial infarction undergoing primary PCI: a systematic review and meta-analysis","volume":"398","author":"Alizadehasl","year":"2025","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"165770","DOI":"10.1016\/j.bbadis.2020.165770","article-title":"SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models","volume":"1866","author":"Andreadou","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1586\/17512433.2013.827399","article-title":"The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment","volume":"6","author":"Andrianesis","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ejhf.3560","article-title":"Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)","volume":"27","author":"Carberry","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","article-title":"Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease","volume":"14","author":"Dai","year":"2023","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijcard.2023.03.002","article-title":"Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial)","volume":"379","author":"Dayem","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"26136","DOI":"10.31083\/RCM26136","article-title":"Cardiovascular outcome of the SGLT2 inhibitor in acute myocardial infarction: a meta-analysis","volume":"26","author":"Hu","year":"2025","journal-title":"Rev. Cardiovasc Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovasc Diabetol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2019-11-3","article-title":"DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure","volume":"9","author":"Kaplinsky","year":"2020","journal-title":"Drugs Context"},{"key":"B12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40256-024-00662-4","article-title":"Empagliflozin effects in patients with ST-Elevation myocardial infarction undergoing primary PCI: the EMI-STEMI randomized clinical trial","volume":"24","author":"Khani","year":"2024","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.31083\/j.rcm2505154","article-title":"Effect of SGLT-2 inhibitors on prognosis in diabetic patients with acute myocardial infarction: a systematic review and meta-analysis","volume":"25","author":"Li","year":"2024","journal-title":"Rev. Cardiovasc Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00232-021-00192-z","article-title":"The Na\/K-ATPase signaling and SGLT2 inhibitor-mediated cardiorenal protection: a crossed road?","volume":"254","author":"Liu","year":"2021","journal-title":"J. Membr. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","article-title":"Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease","volume":"32","author":"Mima","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"B17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"175221","DOI":"10.1016\/j.ejphar.2022.175221","article-title":"Endoplasmic reticulum stress: a common pharmacologic target of cardioprotective drugs","volume":"931","author":"Mooradian","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-016-0403-8","article-title":"The EMPA-REG outcome study: critical appraisal and potential clinical implications","volume":"15","author":"Perseghin","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.120.051122","article-title":"Two tales: one story: EMPEROR-reduced and DAPA-HF","volume":"142","author":"Verma","year":"2020","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur. Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s10741-022-10220-2","article-title":"Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?","volume":"27","author":"Wichaiyo","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.23736\/S2724-5683.23.06478-5","article-title":"Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus","volume":"72","author":"Zhou","year":"2024","journal-title":"Minerva Cardiol. Angiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699066\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:33:05Z","timestamp":1764253985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699066\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":29,"alternative-id":["10.3389\/fphar.2025.1699066"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1699066","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1699066"}}